News

Leidos Holdings (LDOS) stock has come under pressure after the Defense Health Agency signaled plans to reduce reliance on the company as lead integrator for its electronic health record program, prompting downgrades from Jefferies and BofA Securities. See our latest analysis for Leidos Holdings. At a share price of $108.67, Leidos Holdings has seen momentum fade, with the 7-day share price return declining 10.70% and the 90-day share price return down 34.52%, although the 3-year total...

(Updates to include BofA's commentary) BofA Securities Downgrades Leidos (LDOS) to neutral from b

Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls

Leidos Holdings, Inc. (NYSE:LDOS) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On June 5, Jefferies downgraded Leidos Holdings, Inc. (LDOS)’s stock to “Hold” from “Buy” and reduced the price objective to $140 from $185. The firm highlighted limited organic growth prospects, along with concerns related to the company’s health business. […]

Leidos Holdings (NYSE:LDOS) has delivered a new Joint Management Tool to the U.S. military and defense agencies. The tool is designed to modernize satellite communications and operational oversight for global forces. JMT is now supporting the Department of War, DISA, and U.S. Space Command with real time situational awareness and more efficient SATCOM operations. For investors watching defense technology, this update puts Leidos Holdings (NYSE:LDOS) in focus as it rolls out a material...